Samuil Umansky

6433155, Aug 13, 2002

Sep 24, 1997

08/937067

Samuil Umansky - Richmond CA
Hovsep Melkonyan - Albany CA

Tanox, Inc. - Houston TX

C07H 2104

536 235, 536 231, 536 243, 536 2431, 536 2433, 435 691, 4353201, 435325

An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of SARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.

6492144, Dec 10, 2002

Aug 3, 2000

09/634732

Samuil R. Umansky - Richmond CA
Anatoly V. Lichtenstein - Moscow, RU
Hovsep S. Melkonyan - Albany CA

Diagen Corporation - Richmond CA

C12P 1934

435 912, 435 6, 435 911, 436 94, 536 2433, 536 254, 536 2541

Described are non-invasive methods of detecting the presence of specific nucleic acid sequences as well as nucleic acid modifications and alterations by analyzing urine samples for the presence of transrenal nucleic acids. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences and fetal sequences that contained modified nucleotides by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid modifications for the diagnosis of diseases, such as cancer and pathogen infections, and detection of genetic predisposition to various diseases. The invention specifically encompasses methods of analyzing specific nucleic acid modifications for the monitoring of cancer treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs. The invention also encompasses methods for evaluating the effects of environmental factors and aging on the genome.

7045596, May 16, 2006

May 14, 2002

10/146474

Samuil Umansky - Richmond CA, US
Hovsep Melkonyan - Albany CA, US

Tanox, Inc. - Houston TX

C07K 14/00

530350, 530300, 536 231, 536 235, 536 2641, 4241841, 4241851

An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.

7045604, May 16, 2006

Nov 20, 2002

10/301764

Samuil Umansky - Richmond CA, US
Hovsep Melkonyan - Albany CA, US

Tanox, Inc. - Houston TX

C07K 16/18

5303879, 530300, 530350, 5303873, 5303881, 5303891, 5303913

An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.

7259273, Aug 21, 2007

Sep 26, 2005

11/236429

John G. Goddard - San Francisco CA, US
Donald H. Picker - Warren NJ, US
Samuil R. Umansky - Richmond CA, US
Steven Price - Aylesbury, Bucks, GB
Jac C. Wijkmans - Abingdon, Oxon, GB
Edward A. Boyd - Didcot, Oxon, GB
Anthony D. Baxter - Abingdon, Oxon, GB

C07C 305/00
A61K 31/66

558 20, 554 79, 514 75, 562567

The invention provides anti-apoptotic compositions containing lysophosphatidic acids and methods for making and using the compositions. Such compositions may also contain LPA potentiating agents, including proteins, lipid membrane structures and polymers such as polyethylene glycols. The compositions can additionally contain other pharmaceutically effective agents such as drugs, antibiotics, wound healing agents and antioxidants.

7576187, Aug 18, 2009

Jul 14, 2006

11/457779

Samuil Umansky - Richmond CA, US
Hovsep Melkonyan - Albany CA, US

Genentech, Inc. - South San Francisco CA

C07K 16/18

5303879, 530350, 5303871, 5303873, 5303877, 53038824, 5303891, 5303913

An isolated polynucleotide at least 60% homologous to SEQ ID NO: 1, 3, 5 or 18 encoding a SARP polypeptide; vectors comprising a polynucleotide sequence encoding at least 11 consecutive amino acids of αSARP polypeptide; a host cell transformed with an isolated polynucleotide or vector; antibodies specific for SARP and use of such polynucleotides and antibodies in diagnostic and therapeutic method. Therapeutic uses of antibodies and polynucleotides of sarp. Methods for treating diseases related to the regulation of SARP expression in tissue and bodily fluid samples, including cancers.

20020119478, Aug 29, 2002

Nov 7, 2001

10/007607

Samuil Umansky - Richmond CA, US
Anatoly Lichtenstein - Moscow, RU
Hovsep Melkonyan - Albany CA, US

Diagen Corporation - Richmond CA

C12Q001/68
C12P019/34

435/006000, 435/091200

Described are non-invasive methods of detecting the presence of specific nucleic acid sequences as well as nucleic acid modifications and alterations by analyzing urine samples for the presence of transrenal nucleic acids. More specifically, the present invention encompasses methods of detecting specific fetal nucleic acid sequences and fetal sequences that contained modified nucleotides by analyzing maternal urine for the presence of fetal nucleic acids. The invention further encompasses methods of detecting specific nucleic acid modifications for the diagnosis of diseases, such as cancer and pathogen infections, and detection of genetic predisposition to various diseases. The invention specifically encompasses methods of analyzing specific nucleic acid modifications for the monitoring of cancer treatment. The invention further encompasses methods of analyzing specific nucleic acids in urine to track the success of transplanted cells, tissues and organs. The invention also encompasses methods for evaluating the effects of environmental factors and aging on the genome.

20060063738, Mar 23, 2006

Sep 26, 2005

11/236403

Ian Bathurst - Kensington CA, US
Matthew Foehr - San Francisco CA, US
J. Goddard - San Francisco CA, US
Samuil Umansky - Richmond CA, US
John Bradley - Brookline MA, US
Donald Picker - Warren NJ, US

Sky High, LLC - Evanston IL

A61K 31/685

514078000

The present invention provides therapeutic compositions containing lysophosphatidic acids, methods for making the compositions, and methods of use thereof.